Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...

Sanofi CEO Paul Hudson stated: “We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already ...

L’Oréal remains an important shareholder of Sanofi and is fully supportive of the company’s value creation strategy,” said ...

PARIS — L’Oréal has agreed to sell about 29.6 million Sanofi shares to Sanofi for approximately 3 billion euros.

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.